The pharmaceutical industry stands at a pivotal crossroads where digital health technologies aren’t just optional add-ons but existential imperatives. The eight trends outlined—from AI-driven drug discovery to in silico clinical…
The relentless march of medical technology often promises to revolutionize healthcare, but as industry professionals, we must pause and critically evaluate when innovation becomes unsettling or ethically questionable. The examples…
The recent online meeting between the Clinical Trials Transformation Initiative (CTTI)/FDA Patient Engagement Collaborative (PEC) and the European Medicines Agency (EMA) Patients and Consumers Working Party (PCWP) highlights a persistent…
The upcoming joint meeting between the CTTI/FDA Patient Engagement Collaborative (PEC) and the EMA Patients and Consumers Working Party (PCWP) is being heralded as a milestone in cross-continental patient involvement.…
The recent overhaul at STAAR, driven by an activist investor that resulted in the ousting of both the CEO and board chair, is more than just another headline in healthcare…
The so-called ‘Great Healthcare Plan’ is emblematic of a broader issue in healthcare policy communication: ambiguity that hinders strategic marketing and stakeholder engagement. For healthcare marketers, clarity is non-negotiable. This…
The current industry obsession with “strategic leadership” in healthcare risks becoming a buzzword devoid of actionable insight. While the article rightly positions leadership as central to progress, it stops short…
The recent declaration by a medtech venture capital firm that kidney care is entering a new era of innovation is both timely and expected, but it warrants a critical lens.…
The tepid dealmaking observed at JPM26 should not be mistaken for stagnation in the healthcare sector. Instead, it highlights a deeper recalibration as pharmaceutical companies brace for the impending patent…
The announcement of the fourth bilateral meeting between the European Medicines Agency (EMA) and the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) might seem routine, but it underscores a persistent challenge…